Yusuf Hameed/LinkedIn
May 23, 2026, 16:44
Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
Yusuf Hameed, Anesthesiologist, Principal of Angel Investor, shared a post on X:
“Promising news for hemophilia A patients:
Many patients in Sangamo Therapeutics‘ giroctocogene fitelparvovec trials maintain strong benefits (fewer bleeds, lower treatment burden) through approximately 3-4 years of follow-up—a real advance vs lifelong prophylaxis.
Long-term (5-10+ years) data is still maturing, with individual results varying.
Big upside:
One-time gene therapy could yield major lifetime cost savings vs $300K–$800K+/yr prophylaxis (often more than $20M lifetime). Screening plus monitoring key.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia